From: Benefits and harms of medical cannabis: a scoping review of systematic reviews
Author, year | Search dates; # databases searched | Funding source | Nstudies | Illness/condition | Intervention/comparator* | Outcomes | Conclusions from data | AMSTAR-2 rating |
---|---|---|---|---|---|---|---|---|
Walitt, 2016 [39] | To Apr 26, 2016; 3 | No funding | 2 | Fibromyalgia | I: Synthetic cannabinoids C: Placebo; Amitriptyline | • Pain • Anxiety • QoL • Fatigue • Depression • Insomnia • Mood states • Withdrawal due to AEs | Reported SBS for all outcomes (vs. placebo or amitriptyline) | M |
Fitzcharles, 2016 [49] | Sept 2013 (updated Jan 2015); 11 | NR | 4 | Rheumatic diseases (inflammatory arthritis, OA, soft tissue rheumatism, and FM) | I: Plant-derived and synthetic cannabinoids C: Placebo; amitriptyline | • Pain • Sleep quality • Disease activity score • QoL • Sleep measures • Withdrawal due to AEs • Total AEs | Reported SBS for pain, sleep, disease activity, and withdrawal due to adverse events (vs. placebo); reported SBS for QoL, sleep measures, withdrawal due to adverse events, and total adverse events (vs. amitriptyline) | M |
Richards, 2012 [51] | Inception to Nov 2010; 4 | Non-profit | 1 | RA | I: Plant-derived cannabinoids C: Placebo | • Movement and morning pain • Total intensity of pain • Pain at present • Sleep • Withdrawal due to adverse events • Total adverse events | Favors intervention for movement and morning pain, sleep NRS, and total adverse events. No statistically significant difference between groups for total intensity of pain, pain at present, and withdrawal due to adverse events | M |
Macfarlane, 2011 [73] | Start search date varies by database to Aug 2010; 7 | Non-profit | 1 | RA | I: Plant-derived cannabinoids C: Placebo | • Pain • Quality of sleep • 28-joint disease activity score | Only one study included | L |